COST-UTILITY AND BUDGET IMPACT ANALYSES OF TUMOR NECROSIS FACTOR INHIBITOR BIOLOGICS AND BIOSIMILARS VERSUS RITUXIMAB IN THAI PATIENTS WITH ACTIVE RHEUMATOID ARTHRITIS

被引：0
|
作者：
Leelahavarong, P. [1 ]
Osiri, M. [2 ]
Koolvisoot, A. [3 ]
Prawjaeng, J. [4 ]
Budtarad, N. [1 ]
机构：
[1] Mahidol Univ, Siriraj Hosp, Fac Med, Siriraj Hlth Policy Unit, Bangkok, Thailand
[2] Chulalongkorn Univ, Div Rheumatol, Dept Med, Fac Med, Pathumwan, Thailand
[3] Mahidol Univ, Siriraj Hosp, Fac Med, Div Rheumatol, Bangkok, Thailand
[4] Mahidol Univ, Fac Med, Siriraj Hlth Policy Unit, Siriraj Hosp, Bangkok, Thailand
来源：
VALUE IN HEALTH | 2023年 / 26卷 / 12期
关键词：
D O I：
暂无
中图分类号：
F [经济];
学科分类号：
02 ;
摘要：
EE424
引用
收藏
页码：S132 / S133
页数：2
相关论文
共 50 条
  • [1] Tofacitinib Versus Non-Tumor Necrosis Factor Biologics for Patients With Active Rheumatoid Arthritis
    Nakamura, Yukio
    Suzuki, Takako
    Yamazaki, Hideshi
    Kato, Hiroyuki
    ARCHIVES OF RHEUMATOLOGY, 2018, 33 (02) : 154 - 159
  • [2] THE COMPARISONS OF BIOLOGICS WITH METHOTREXATE FOR TREATING RHEUMATOID ARTHRITIS PATIENTS IN TAIWAN: THE USE OF COST-UTILITY ANALYSIS AND BUDGET IMPACT ANALYSIS
    Li, C.
    Chou, P.
    Chang, C.
    Fann, C. S.
    VALUE IN HEALTH, 2016, 19 (07) : A915 - A915
  • [3] COST-UTILITY ANALYSIS OF TREATMENT OPTIONS AFTER INITIAL TUMOR NECROSIS FACTOR INHIBITOR THERAPY FAILURE IN PATIENTS WITH RHEUMATOID ARTHRITIS
    Karpes Matusevich, A. R.
    Lal, L.
    Wenyaw, C.
    Swint, J. M.
    Cantor, S. B.
    Suarez-Almazor, M. E.
    Lopez-Olivo, M. A.
    VALUE IN HEALTH, 2020, 23 : S219 - S219
  • [4] Cost-utility analysis of treatment options after initial tumor necrosis factor inhibitor therapy discontinuation in patients with rheumatoid arthritis
    Matusevich, Aliza R. Karpes
    Lai, Lincy S.
    Chan, Wenyaw
    Swint, J. Michael
    Cantor, Scott B.
    Suarez-Almazor, Maria E.
    Lopez-Olivo, Maria A.
    JOURNAL OF MANAGED CARE & SPECIALTY PHARMACY, 2021, 27 (01): : 73 - 83
  • [5] Cost-utility analysis of second-line therapy with rituximab compared to tumour necrosis factor inhibitors in rheumatoid arthritis
    Lopatina, Elena
    Marshall, Deborah A.
    Coupal, Louis
    Le Lorier, Jacques
    Choquette, Denis
    CURRENT MEDICAL RESEARCH AND OPINION, 2021, 37 (01) : 157 - 166
  • [6] Budget Impact of Sequential Treatment with Biologics, Biosimilars, and Targeted Synthetic Disease-Modifying Antirheumatic Drugs in Thai Patients with Rheumatoid Arthritis
    Manathip Osiri
    Piyameth Dilokthornsakul
    Sasitorn Chokboonpium
    Pichaya Suthipinijtham
    Ajchara Koolvisoot
    Advances in Therapy, 2021, 38 : 4885 - 4899
  • [7] Budget Impact of Sequential Treatment with Biologics, Biosimilars, and Targeted Synthetic Disease-Modifying Antirheumatic Drugs in Thai Patients with Rheumatoid Arthritis
    Osiri, Manathip
    Dilokthornsakul, Piyameth
    Chokboonpium, Sasitorn
    Suthipinijtham, Pichaya
    Koolvisoot, Ajchara
    ADVANCES IN THERAPY, 2021, 38 (09) : 4885 - 4899
  • [8] Cost-utility analysis of rituximab as a new therapeutic option for rheumatoid arthritis patients in Canada
    Mistry, B.
    McCormick, J.
    Diamantopoulos, A.
    Kielhorn, A.
    VALUE IN HEALTH, 2006, 9 (06) : A222 - A222
  • [9] Cost-utility of different treatment strategies after the failure of tumour necrosis factor inhibitor in rheumatoid arthritis in the Finnish setting
    Hallinen, Taru A.
    Soini, Erkki J. O.
    Eklund, Kari
    Puolakka, Kari
    RHEUMATOLOGY, 2010, 49 (04) : 767 - 777
  • [10] COST-UTILITY ANALYSIS OF TUMOR NECROSIS FACTOR-ALPHA INHIBITORS FOR THE TREATMENT OF RHEUMATOID ARTHRITIS USING A MARKOV MODEL
    Nguyen, C. M.
    Mendes, M.
    Bounthavong, M.
    Christopher, M.
    Morreale, A. P.
    VALUE IN HEALTH, 2010, 13 (03) : A127 - A128
12345